Fosun Pharma Secures China Approval for Two Drugs

MT Newswires Live

Aug 10

China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), according to separate disclosures filed with the Hong Kong Exchange on Friday.

The approvals cover Levosalbutamol Hydrochloride Nebuliser Solution, developed by Fosun Pharma (Xuzhou), and Dobutamine Hydrochloride Injection, developed by Shanghai Zhaohui Pharmaceutical Company.

Levosalbutamol Hydrochloride Nebuliser Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children aged six years and older with reversible obstructive airway disease.

Dobutamine Hydrochloride Injection is approved for the short-term supportive treatment of heart failure caused by reduced myocardial contractility.

Fosun Pharma's Hong Kong-listed shares rose 3%, while its Shanghai shares edged up 2% in early-morning trade on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2658609444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658609444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658609444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658609444","market":"us","top_or_hot":-1,"title":"Fosun Pharma Secures China Approval for Two Drugs","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (HKG:2196, SHA:600196), according to separate disclosures filed with the Hong Kong Exchange on Friday.</p><p>The approvals cover Levosalbutamol Hydrochloride Nebuliser Solution, developed by Fosun Pharma (Xuzhou), and Dobutamine Hydrochloride Injection, developed by Shanghai Zhaohui Pharmaceutical Company.</p><p>Levosalbutamol Hydrochloride Nebuliser Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children aged six years and older with reversible obstructive airway disease.</p><p>Dobutamine Hydrochloride Injection is approved for the short-term supportive treatment of heart failure caused by reduced myocardial contractility.</p><p>Fosun Pharma's Hong Kong-listed shares rose 3%, while its Shanghai shares edged up 2% in early-morning trade on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Secures China Approval for Two Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Secures China Approval for Two Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-10 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (HKG:2196, SHA:600196), according to separate disclosures filed with the Hong Kong Exchange on Friday.</p><p>The approvals cover Levosalbutamol Hydrochloride Nebuliser Solution, developed by Fosun Pharma (Xuzhou), and Dobutamine Hydrochloride Injection, developed by Shanghai Zhaohui Pharmaceutical Company.</p><p>Levosalbutamol Hydrochloride Nebuliser Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children aged six years and older with reversible obstructive airway disease.</p><p>Dobutamine Hydrochloride Injection is approved for the short-term supportive treatment of heart failure caused by reduced myocardial contractility.</p><p>Fosun Pharma's Hong Kong-listed shares rose 3%, while its Shanghai shares edged up 2% in early-morning trade on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658609444","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658609444","pubTimestamp":1786327325,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), according to separate ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0096":"民营医院","BK0060":"抗癌","BK1515":"抗疫概念","BK1191":"制药","BK0187":"一线龙头","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"复星医药两种药物获得中国批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9},"content_text":"China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), according to separate disclosures filed with the Hong Kong Exchange on Friday.The approvals cover Levosalbutamol Hydrochloride Nebuliser Solution, developed by Fosun Pharma (Xuzhou), and Dobutamine Hydrochloride Injection, developed by Shanghai Zhaohui Pharmaceutical Company.Levosalbutamol Hydrochloride Nebuliser Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children aged six years and older with reversible obstructive airway disease.Dobutamine Hydrochloride Injection is approved for the short-term supportive treatment of heart failure caused by reduced myocardial contractility.Fosun Pharma's Hong Kong-listed shares rose 3%, while its Shanghai shares edged up 2% in early-morning trade on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}